Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Avis To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Avis between February 16, 2024 and February 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, May 31, 2025 /PRNewswire/ -- Faruqi & Faruqi, L ...

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Avis Budget Group, Inc. (NASDAQ: CAR). Shareholders who purchased shares of CAR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/avis-budget-loss-submission-form/?id=150515&from=3 CLASS PERIOD: February 16, ...

NEW YORK, May 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Avis Budget Group, Inc. (NASDAQ: CAR).Shareholders who purchased shares of CAR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/avis-budget-loss-submission-form/?id=150498&from=4CLASS PERIOD: February 16, 2024 to ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Avis Budget Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Avis Budget securities between February 16, 2024, and February 10, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 24, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, Avis Budget made false and misleading statements regarding its fleet rotation plan, which significantly accelerated in Q4 2024 [5]. - This acceleration reportedly shortened the useful life of Avis Budget's vehicles in the Americas segment, leading to billions of dollars in impairment charges and substantial losses [5]. - The lawsuit claims that these actions had a significant negative impact on Avis Budget's financial results, overstating the company's financial and business prospects [5].

Group 1 - Avis Budget Group (NASDAQ: CAR) has experienced a significant rally, with shares increasing by 9% from the previous year, following lows in March [1] - The company's business model is highly leveraged to the residual value of used cars, positioning it as a potential beneficiary in the current market environment [1] - The analyst emphasizes a contrarian investment strategy based on macroeconomic views and turnaround stories to achieve favorable risk/reward profiles [1]

Company Overview - CARsgen Therapeutics Holdings Limited is focused on developing innovative CAR T-cell therapies to address unmet clinical needs in hematologic malignancies, solid tumors, and autoimmune diseases [3] - The company has established end-to-end capabilities for CAR T-cell research and development, including target discovery, preclinical research, clinical development, and commercial-scale production [3] - CARsgen aims to improve the safety profile, enhance efficacy in treating solid tumors, and reduce treatment costs of CAR T-cell therapies [3] Product Development - Satri-cel is an autologous CAR T-cell product candidate targeting Claudin18.2, with a primary focus on treating Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) and pancreatic cancer [2] - The product has received Priority Review from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for patients who have failed at least two prior lines of therapy [1] - Satri-cel has been granted Breakthrough Therapy Designation by the CDE in March 2025 and has received Orphan Drug designation from the U.S. FDA in September 2020 [2] Clinical Trials - Ongoing clinical trials for Satri-cel include a confirmatory Phase II trial for advanced G/GEJA in China, a Phase Ib trial for pancreatic cancer adjuvant therapy, and a Phase 1b/2 trial for advanced gastric or pancreatic adenocarcinoma in North America [2] - The company is also conducting investigator-initiated trials to explore the use of Satri-cel as a consolidation treatment following adjuvant therapy in patients with resected G/GEJA [2]

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Avis Budget Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Avis Budget securities between February 16, 2024, and February 10, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 24, 2025 [3][6]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, Avis Budget made false and misleading statements regarding its fleet rotation plan, which significantly accelerated in Q4 2024 [5]. - This acceleration reportedly shortened the useful life of Avis Budget's vehicles in the Americas segment, leading to billions of dollars in impairment charges and substantial losses [5]. - The lawsuit claims that these actions had a significant negative impact on Avis Budget's financial results, overstating the company's financial and business prospects [5].

Core Viewpoint - CARsgen Therapeutics announced the availability of research results from a confirmatory Phase II clinical trial of satricabtagene autoleucel ("satri-cel") for advanced gastric/gastroesophageal junction cancer, highlighting its potential as a new standard of care in this indication [1][9]. Group 1: Clinical Trial Overview - The Phase II trial (CT041-ST-01) was a multicenter, randomized controlled trial conducted in China, comparing satri-cel to standard of care in patients with CLDN18.2 positive advanced G/GEJC who had failed at least two prior treatments [2][4]. - The primary endpoint was progression-free survival (PFS) assessed by an Independent Review Committee (IRC), with overall survival (OS) as a key secondary endpoint [2][4]. Group 2: Patient Demographics and Treatment - A total of 156 patients were randomized (2:1) to receive either satri-cel (n=104) or treatment of physician's choice (TPC) (n=52), with a median of 2 prior systemic therapies in both arms [3][4]. - In the TPC arm, patients could receive subsequent satri-cel if they experienced disease progression or drug intolerance [3]. Group 3: Efficacy Results - In the intention-to-treat (ITT) population, the satri-cel arm showed a median PFS of 3.25 months compared to 1.77 months in the TPC arm, representing a 63% reduction in the risk of disease progression or death [5]. - The median OS for the satri-cel arm was 7.92 months versus 5.49 months for the TPC arm, indicating over a 30% reduction in mortality risk [5]. Group 4: Treatment Benefits in mITT Population - In the modified intention-to-treat (mITT) population, the median PFS was 4.37 months for satri-cel versus 1.84 months for TPC, showing a 70% reduction in risk of disease progression or death [6]. - The median OS in the mITT population was 8.61 months for satri-cel compared to 5.49 months for TPC, corresponding to a 40% reduction in mortality risk [6]. Group 5: Safety Profile - Satri-cel demonstrated a favorable safety profile, with only 4 cases of Grade 3 cytokine release syndrome (CRS) reported and no Grade 4-5 CRS events observed [8]. - No immune effector cell-associated neurotoxicity syndrome (ICANS) was reported [8]. Group 6: Significance of Findings - This trial represents the first confirmatory randomized controlled trial of CAR-T therapy in solid tumors, demonstrating significant PFS improvement and clinically meaningful OS benefits for patients with advanced G/GEJC [9]. - The results support the potential of satri-cel as a new standard of care for this patient population [9]. Group 7: About Satri-cel - Satri-cel is an autologous CAR T-cell product candidate targeting Claudin18.2, with ongoing trials for various indications including advanced gastric/gastroesophageal junction cancer and pancreatic cancer [10]. - The product has received Breakthrough Therapy Designation in China and Regenerative Medicine Advanced Therapy designation from the U.S. FDA, indicating its potential significance in treating advanced G/GEJC [10]. Group 8: About CARsgen Therapeutics - CARsgen Therapeutics is focused on developing innovative CAR T-cell therapies to address unmet clinical needs across various malignancies and diseases [11]. - The company has established comprehensive capabilities for CAR T-cell research and development, aiming to enhance safety and efficacy while reducing treatment costs [11].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Avis Budget Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on June 24, 2025 [1]. Group 1: Class Action Details - Investors who purchased Avis Budget securities between February 16, 2024, and February 10, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit claims that Avis Budget made false and misleading statements regarding its fleet rotation plan, which led to significant financial impairments and losses [5]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering substantial amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving notable recoveries, including over $438 million in 2019 [4]. Group 3: Case Specifics - The lawsuit alleges that Avis Budget's accelerated fleet rotation plan shortened the useful life of its vehicles, resulting in billions of dollars in impairment charges and negatively impacting financial results [5].